Degradation and clearance of methotrexate in children with osteosarcoma receiving high-dose infusion. 1978

Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow

Plasma methotrexate (MTX) concentrations were quantitated in 34 patients after 127 high-dose (35--350 mg/kg) infusions with citrovorum factor rescue. Significant linear correlations have been obtained between methotrexate dosage and concentrations in plasma at 6 and 24 hours after the initiation of the therapy. However, similar trends have not been observed when 48- and 72-hour samples were analyzed. Clinical toxicity was not serious when the methotrexate level in plasma was less than 4.5 X 10(-6) M at 48 hours after the start of a six-hour infusion in children. A minimal four-hour steady-state methotrexate plasma level can be maintained during a six-hour infusion. Children excrete methotrexate at a faster rate than adults; the half-life of MTX during the first phase of plasma clearance curve is one hour shorter in children. Urinary analyses have indicated that substantial methotrexate is metabolized. The chemical nature of these components has not been identified. Further, the urinary metabolic profiles varied among patients.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D002955 Leucovorin The active metabolite of FOLIC ACID. Leucovorin is used principally as an antidote to FOLIC ACID ANTAGONISTS. Calcium Leucovorin,Citrovorum Factor,Folinic Acid,N(5)-Formyltetrahydrofolate,5-Formyltetrahydrofolate,5-Formyltetrahydropteroylglutamate,Calcium Folinate,Folinic Acid-SF,Leucovorin, (D)-Isomer,Leucovorin, (DL)-Isomer,Leucovorin, (R)-Isomer,Leucovorin, Calcium (1:1) Salt,Leucovorin, Calcium (1:1) Salt, (DL)-Isomer,Leucovorin, Calcium (1:1) Salt, Pentahydrate,Leucovorin, Monosodium Salt,Leukovorin,Leukovorum,Wellcovorin,5 Formyltetrahydrofolate,5 Formyltetrahydropteroylglutamate,Acid, Folinic,Factor, Citrovorum,Folinate, Calcium,Folinic Acid SF,Leucovorin, Calcium,Monosodium Salt Leucovorin
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
February 1989, JPMA. The Journal of the Pakistan Medical Association,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
August 1982, Nihon Seikeigeka Gakkai zasshi,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
June 1996, Hiroshima journal of medical sciences,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
February 2017, Oncotarget,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
January 1999, Pediatric dermatology,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
January 2021, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
December 2001, The Annals of pharmacotherapy,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
December 2008, The Lancet. Oncology,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
April 2004, Cancer,
Y M Wang, and P Y Kim, and E Lantin, and D C van Eys, and M M Romsdahl, and W W Sutow
January 1981, Cancer chemotherapy and pharmacology,
Copied contents to your clipboard!